Venetoclax combinations in mutant AML subtypes: IDH1/2
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Daniel Pollyea, University of Colorado School of Medicine, Aurora, US, about venetoclax combina...
25 Jan 20216min
Venetoclax combinations in mutant AML subtypes podcast: FLT3
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US, about venetoclax combinations in patients ...
20 Jan 202112min
Introduction to a series of podcasts on the use of venetoclax combinations in mutation subtypes of AML
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Courtney D. DiNardo, MD Anderson Cancer Center, Houston, US, about the use of venetoclax combin...
20 Jan 20218min
How close are we to offering treatment tailored to mutational profile?
During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES. In this ...
8 Jul 20205min
Approaches and emerging therapies for TP53 AML
During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to a member of our steering committee, Naval Daver, The University of Texas MD Anderson Cancer Center, Houston,...
1 Jul 202014min
How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the AML Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San-Francisco, US ...
24 Jun 202024min
Can CD47 antibody therapy be safely used for AML and MDS?
During the 25th Congress of the European Hematology Association (EHA), the AML Hub hosted a discussion between David Sallman, Moffitt Cancer Center, Tampa, US, and Steering Committee Member Naval Dave...
22 Jun 202014min
How does the type of prior treatment affect the risk of therapy-related myeloid neoplasms?
During the American Society of Clinical Oncology (ASCO) Annual Meeting, Alexander Maurer from the AML Hub hosted a group discussion with Michael Ozga and Caner Saygin, both from The Ohio State Univers...
9 Jun 202020min
